A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
Primary Purpose
Schizophrenia
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
olanzapine
atomoxetine
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Schizophrenia
Eligibility Criteria
Inclusion Criteria: Must have a clinical diagnosis of Schizophrenia Must be at least 18 years of age and not older than 55 years of age Must have been stable on a dose of Abilify, Risperdal, Seroquel, or Zyprexa for the past 8 weeks Women of childbearing potential must be using a medically accepted means of contraception Must be able to swallow capsules Exclusion Criteria: Has serious health problems other than Schizophrenia Takes an antidepressant for depression Takes insulin for diabetes Have a history of alcohol or drug dependence (except for nicotine and caffeine) within the past 6 months
Sites / Locations
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician.
- For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
- For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
- For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00089869
Brief Title
A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
Study Type
Interventional
2. Study Status
Record Verification Date
July 2006
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Eli Lilly and Company
4. Oversight
5. Study Description
Brief Summary
Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
olanzapine
Intervention Type
Drug
Intervention Name(s)
atomoxetine
Intervention Type
Drug
Intervention Name(s)
placebo
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Must have a clinical diagnosis of Schizophrenia
Must be at least 18 years of age and not older than 55 years of age
Must have been stable on a dose of Abilify, Risperdal, Seroquel, or Zyprexa for the past 8 weeks
Women of childbearing potential must be using a medically accepted means of contraception
Must be able to swallow capsules
Exclusion Criteria:
Has serious health problems other than Schizophrenia
Takes an antidepressant for depression
Takes insulin for diabetes
Have a history of alcohol or drug dependence (except for nicotine and caffeine) within the past 6 months
Facility Information:
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
Cerritos
State/Province
California
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician.
City
Chula Vista
State/Province
California
Country
United States
Facility Name
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
City
Garden Grove
State/Province
California
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
San Diego
State/Province
California
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
New Haven
State/Province
Connecticut
Country
United States
Facility Name
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
City
New Haven
State/Province
Connecticut
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
Atlanta
State/Province
Georgia
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
Chicago
State/Province
Illinois
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
Indianapolis
State/Province
Indiana
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
Iowa City
State/Province
Iowa
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
Minneapolis
State/Province
Minnesota
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
Lebanon
State/Province
New Hampshire
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
New York
State/Province
New York
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
Butner
State/Province
North Carolina
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
Chapel Hill
State/Province
North Carolina
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
Okalahoma City
State/Province
Oklahoma
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
Austin
State/Province
Texas
Country
United States
Facility Name
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
City
Irving
State/Province
Texas
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
Irvin
State/Province
Texas
Country
United States
Facility Name
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
City
San Antonio
State/Province
Texas
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
We'll reach out to this number within 24 hrs